Pfizer faces disappointment with anticancers after more Phase III failures
This article was originally published in Scrip
Executive Summary
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - which could spell the end for the drug in the disease - and figitumumab (CP-751,871), one of the most advanced insulin growth factor-1 (IGF-1) receptor antagonists in development, failed a second Phase III trial in advanced non-small cell lung cancer (NSCLC).